Comparison of the effects of acetyl L-carnitine and amantadine for the treatment of fatigue in multiple sclerosis: Results of a pilot, randomised, double-blind, crossover trial

Valentina Tomassini, Carlo Pozzilli, Emanuela Onesti, Patrizio Pasqualetti, Fabiana Marinelli, Angela Pisani, Cesare Fieschi

Research output: Contribution to journalArticle

103 Citations (Scopus)

Abstract

Treatment with acetyl L-carnitine (ALCAR) has been shown to improve fatigue in patients with chronic fatigue syndrome, but there have been no trials on the effect of ALCAR for treating fatigue in multiple sclerosis (MS). To compare the efficacy of ALCAR with that of amantadine, one of the drugs most widely used to treat MS-related fatigue, 36 MS patients presenting fatigue were enrolled in a randomised, double-blind, crossover study. Patients were treated for 3 months with either amantadine (100 mg twice daily) or ALCAR (1 g twice daily). After a 3-month washout period, they crossed over to the alternative treatment for 3 months. Patients were rated at baseline and every 3 months according to the Fatigue Severity Scale (FSS), the primary endpoint of the study. Secondary outcome variables were: Fatigue Impact Scale (FIS), Beck Depression Inventory (BDI) and Social Experience Checklist (SEC). Six patients withdrew from the study because of adverse reactions (five on amantadine and one on ALCAR). Statistical analysis showed significant effects of ALCAR compared with amantadine for the Fatigue Severity Scale (p=0.039). There were no significant effects for any of the secondary outcome variables. The results of this study show that ALCAR is better tolerated and more effective than amantadine for the treatment of MS-related fatigue.

Original languageEnglish
Pages (from-to)103-108
Number of pages6
JournalJournal of the Neurological Sciences
Volume218
Issue number1-2
DOIs
Publication statusPublished - Mar 15 2004

Fingerprint

Acetylcarnitine
Amantadine
Cross-Over Studies
Multiple Sclerosis
Fatigue
Therapeutics
Chronic Fatigue Syndrome
Checklist
Double-Blind Method
Equipment and Supplies

Keywords

  • Acetyl L-carnitine
  • Amantadine
  • Double-blind crossover trial
  • Fatigue
  • Fatigue Severity Scale
  • Multiple sclerosis

ASJC Scopus subject areas

  • Ageing
  • Clinical Neurology
  • Surgery
  • Developmental Neuroscience
  • Neurology
  • Neuroscience(all)

Cite this

Comparison of the effects of acetyl L-carnitine and amantadine for the treatment of fatigue in multiple sclerosis : Results of a pilot, randomised, double-blind, crossover trial. / Tomassini, Valentina; Pozzilli, Carlo; Onesti, Emanuela; Pasqualetti, Patrizio; Marinelli, Fabiana; Pisani, Angela; Fieschi, Cesare.

In: Journal of the Neurological Sciences, Vol. 218, No. 1-2, 15.03.2004, p. 103-108.

Research output: Contribution to journalArticle

Tomassini, Valentina ; Pozzilli, Carlo ; Onesti, Emanuela ; Pasqualetti, Patrizio ; Marinelli, Fabiana ; Pisani, Angela ; Fieschi, Cesare. / Comparison of the effects of acetyl L-carnitine and amantadine for the treatment of fatigue in multiple sclerosis : Results of a pilot, randomised, double-blind, crossover trial. In: Journal of the Neurological Sciences. 2004 ; Vol. 218, No. 1-2. pp. 103-108.
@article{a4708b01a9bf4b58821dbe1c0dc87708,
title = "Comparison of the effects of acetyl L-carnitine and amantadine for the treatment of fatigue in multiple sclerosis: Results of a pilot, randomised, double-blind, crossover trial",
abstract = "Treatment with acetyl L-carnitine (ALCAR) has been shown to improve fatigue in patients with chronic fatigue syndrome, but there have been no trials on the effect of ALCAR for treating fatigue in multiple sclerosis (MS). To compare the efficacy of ALCAR with that of amantadine, one of the drugs most widely used to treat MS-related fatigue, 36 MS patients presenting fatigue were enrolled in a randomised, double-blind, crossover study. Patients were treated for 3 months with either amantadine (100 mg twice daily) or ALCAR (1 g twice daily). After a 3-month washout period, they crossed over to the alternative treatment for 3 months. Patients were rated at baseline and every 3 months according to the Fatigue Severity Scale (FSS), the primary endpoint of the study. Secondary outcome variables were: Fatigue Impact Scale (FIS), Beck Depression Inventory (BDI) and Social Experience Checklist (SEC). Six patients withdrew from the study because of adverse reactions (five on amantadine and one on ALCAR). Statistical analysis showed significant effects of ALCAR compared with amantadine for the Fatigue Severity Scale (p=0.039). There were no significant effects for any of the secondary outcome variables. The results of this study show that ALCAR is better tolerated and more effective than amantadine for the treatment of MS-related fatigue.",
keywords = "Acetyl L-carnitine, Amantadine, Double-blind crossover trial, Fatigue, Fatigue Severity Scale, Multiple sclerosis",
author = "Valentina Tomassini and Carlo Pozzilli and Emanuela Onesti and Patrizio Pasqualetti and Fabiana Marinelli and Angela Pisani and Cesare Fieschi",
year = "2004",
month = "3",
day = "15",
doi = "10.1016/j.jns.2003.11.005",
language = "English",
volume = "218",
pages = "103--108",
journal = "Journal of the Neurological Sciences",
issn = "0022-510X",
publisher = "Elsevier",
number = "1-2",

}

TY - JOUR

T1 - Comparison of the effects of acetyl L-carnitine and amantadine for the treatment of fatigue in multiple sclerosis

T2 - Results of a pilot, randomised, double-blind, crossover trial

AU - Tomassini, Valentina

AU - Pozzilli, Carlo

AU - Onesti, Emanuela

AU - Pasqualetti, Patrizio

AU - Marinelli, Fabiana

AU - Pisani, Angela

AU - Fieschi, Cesare

PY - 2004/3/15

Y1 - 2004/3/15

N2 - Treatment with acetyl L-carnitine (ALCAR) has been shown to improve fatigue in patients with chronic fatigue syndrome, but there have been no trials on the effect of ALCAR for treating fatigue in multiple sclerosis (MS). To compare the efficacy of ALCAR with that of amantadine, one of the drugs most widely used to treat MS-related fatigue, 36 MS patients presenting fatigue were enrolled in a randomised, double-blind, crossover study. Patients were treated for 3 months with either amantadine (100 mg twice daily) or ALCAR (1 g twice daily). After a 3-month washout period, they crossed over to the alternative treatment for 3 months. Patients were rated at baseline and every 3 months according to the Fatigue Severity Scale (FSS), the primary endpoint of the study. Secondary outcome variables were: Fatigue Impact Scale (FIS), Beck Depression Inventory (BDI) and Social Experience Checklist (SEC). Six patients withdrew from the study because of adverse reactions (five on amantadine and one on ALCAR). Statistical analysis showed significant effects of ALCAR compared with amantadine for the Fatigue Severity Scale (p=0.039). There were no significant effects for any of the secondary outcome variables. The results of this study show that ALCAR is better tolerated and more effective than amantadine for the treatment of MS-related fatigue.

AB - Treatment with acetyl L-carnitine (ALCAR) has been shown to improve fatigue in patients with chronic fatigue syndrome, but there have been no trials on the effect of ALCAR for treating fatigue in multiple sclerosis (MS). To compare the efficacy of ALCAR with that of amantadine, one of the drugs most widely used to treat MS-related fatigue, 36 MS patients presenting fatigue were enrolled in a randomised, double-blind, crossover study. Patients were treated for 3 months with either amantadine (100 mg twice daily) or ALCAR (1 g twice daily). After a 3-month washout period, they crossed over to the alternative treatment for 3 months. Patients were rated at baseline and every 3 months according to the Fatigue Severity Scale (FSS), the primary endpoint of the study. Secondary outcome variables were: Fatigue Impact Scale (FIS), Beck Depression Inventory (BDI) and Social Experience Checklist (SEC). Six patients withdrew from the study because of adverse reactions (five on amantadine and one on ALCAR). Statistical analysis showed significant effects of ALCAR compared with amantadine for the Fatigue Severity Scale (p=0.039). There were no significant effects for any of the secondary outcome variables. The results of this study show that ALCAR is better tolerated and more effective than amantadine for the treatment of MS-related fatigue.

KW - Acetyl L-carnitine

KW - Amantadine

KW - Double-blind crossover trial

KW - Fatigue

KW - Fatigue Severity Scale

KW - Multiple sclerosis

UR - http://www.scopus.com/inward/record.url?scp=0842305087&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0842305087&partnerID=8YFLogxK

U2 - 10.1016/j.jns.2003.11.005

DO - 10.1016/j.jns.2003.11.005

M3 - Article

C2 - 14759641

AN - SCOPUS:0842305087

VL - 218

SP - 103

EP - 108

JO - Journal of the Neurological Sciences

JF - Journal of the Neurological Sciences

SN - 0022-510X

IS - 1-2

ER -